QNCX:NASDAQQuince Therapeutics, Inc. analysis

Quince Therapeutics is trading well below its short‑term averages, with the current price of $0.93 under the 20‑day SMA of 1.06 and the 50‑day SMA of 1.20, while the 200‑day SMA remains far higher at 13.34. Momentum indicators are weak: the RSI sits at 36.8, edging toward oversold, and the MACD line is below its signal, generating a bearish histogram. Volatility is extreme at 79.5% over the past 30 days, beta is elevated at 2.25, and volume trends are decreasing, all pointing to a fragile price environment near the identified support of 0.79 and below the resistance of 1.35. The stock has endured a historic drawdown of -98.2% and reports negative earnings, with a trailing EPS of -10.5 and a forward EPS of -1.17, underscoring severe cash‑burn concerns.
On the catalyst side, the company announced promising Phase 2a results for LAM‑001, an inhaled rapamycin formulation, showing a 67.4‑meter improvement in 6‑minute walk distance and a 33.9% reduction in pulmonary vascular resistance. This data, coupled with the recent acquisition of Orphai Therapeutics and a planned $187 million private placement to fund its pulmonary pipeline, provides a potential upside narrative despite the current financial strain. However, the lack of revenue, negative operating cash flow, and a market‑cap of only $18.3 million keep the risk profile high.